# A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)

> **NCT05398445** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 769 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Rocatinlimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05398445
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-31
- **Primary completion:** 2024-11-28
- **Final completion:** 2025-01-13
- **Target enrollment:** 769 (ACTUAL)
- **Last updated:** 2025-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05398445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05398445, "A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05398445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*